Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RBC BioscienceROCO:6848 -6.36%76 Debt-to-EBITDA is 8.60 as of Jun. 2026, which is 7% above its 10-year median of 8.02. GuruFocus rates ROCO:6848 with a GF Score™ of 76/100 and a GF Value™ of NT$18.17 (Modestly Overvalued). The stock has 12 warning signs investors should review. Among 305 Biotechnology companies, RBC Bioscience ranks worse than 83.28% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for RBC Bioscience's Debt-to-EBITDA or its related term are showing as below:
ROCO:6848'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.15 Med: 8.02 Max: 15.65
Current: 7.82
During the past 9 years, the highest Debt-to-EBITDA Ratio of RBC Bioscience was 15.65. The lowest was 1.15. And the median was 8.02.
ROCO:6848's Debt-to-EBITDA is ranked worse than 83.28% of 305
companies
in the Biotechnology industry
Industry Median: 1.24
vs ROCO:6848: 7.82
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
RBC Bioscience Debt-to-EBITDA Related Terms
RBC Bioscience Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for RBC Bioscience's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6848 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, RBC Bioscience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RBC Bioscience Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RBC Bioscience's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where RBC Bioscience's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
RBC Bioscience (ROCO:6848) has a Debt-to-EBITDA of 8.60 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on RBC Bioscience. This is near median its historical median of 8.02. Over the past decade, RBC Bioscience's Debt-to-EBITDA has ranged from 1.15 to 15.65. According to the industry distribution chart, RBC Bioscience ranks #254 out of 305 companies in the Biotechnology industry, placing it in the top 83.3%.
Is RBC Bioscience's Debt-to-EBITDA too high?
RBC Bioscience's current Debt-to-EBITDA of 8.60 is near median its 10-year median of 8.02. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 15.65. The Biotechnology industry median Debt-to-EBITDA is 1.24. RBC Bioscience's value of 8.60 is 593.5% above this industry median. Based on the distribution chart, RBC Bioscience ranks #254 out of 305 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RBC Bioscience has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RBC Bioscience's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RBC Bioscience ranks #254 out of 305 companies for Debt-to-EBITDA. This places RBC Bioscience in the lower half of its industry. The industry median Debt-to-EBITDA is 1.24. RBC Bioscience's value of 8.60 is 593.5% above this benchmark. Historically, RBC Bioscience's own Debt-to-EBITDA has ranged from 1.15 to 15.65 over the past decade. While the company's 10-year median is 8.02 vs. the industry median of 1.24, RBC Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.24, based on 305 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RBC Bioscience's current Debt-to-EBITDA of 8.60 is 593.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on RBC Bioscience. For the Biotechnology industry, the median Debt-to-EBITDA is 1.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RBC Bioscience's current Debt-to-EBITDA is 8.60, which is near median its own 10-year median of 8.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Bioscience stock overvalued right now?
Based on GuruFocus' analysis, RBC Bioscience (ROCO:6848) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$18.17, compared to a current price of NT$22.10 — trading 21.6% above its estimated fair value. The current Debt-to-EBITDA is 8.60, which is near median its 10-year median of 8.02 and 593.5% above the Biotechnology industry median of 1.24. RBC Bioscience's overall GF Score™ is 76/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For RBC Bioscience (ROCO:6848), the current Debt-to-EBITDA is 8.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RBC Bioscience (ROCO:6848) Overvalued in 2026?
Based on GuruFocus' analysis, RBC Bioscience stock appears to be overvalued.
The current stock price of NT$22.10 is trading 21.6% above its estimated GF Value™ of NT$18.17.
GuruFocus considers RBC Bioscience to be Modestly Overvalued.
Key valuation signals for ROCO:6848:
Debt-to-EBITDA: 8.60 (near median its 10-year median of 8.02)
GF Value™: NT$18.17 vs. price of NT$22.10 (21.6% above fair value)
Industry Position: 593.5% above the Biotechnology median (#254 of 305)
No single metric tells the full story. See the ROCO:6848 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RBC Bioscience Corp is a bio-sciences company. Its products include the manufacture and sale of molecular biological medical diagnosis and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues.
76GF Score
Get the complete analysis for ROCO:6848
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6848 has been successfully added to your 
